Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents

Conclusion: In the IMiD-treated groups we found significant changes of expression of angiogenic genes in responders compared to non-responders, whereas in the bortezomib-based group the difference in expression of angiogenic genes was not significant.

Source: Cancer Genomics and Proteomics - June 29, 2016 Category: Cancer & Oncology Authors: MEDINGER, M., HALTER, J., HEIM, D., BUSER, A., GERULL, S., LENGERKE, C., PASSWEG, J. Tags: Article Source Type: research